What the FDA Relabeling of Abacavir Means for You and Your Patients
An FDA safety alert reported studies linking potentially fatal hypersensitivity reactions with abacavir, an HIV-antiretroviral medication, to a specific HLA-B allele (HLA-B*5701). Testing patients for this allele, prior to receiving abacavir, is now recommended. Dr. O’Kane and Dr. Yao discuss what this means for you and your patients.
- Dennis J. O'Kane, PhD of the Division of Clinical Biochemistry & Immunology at Mayo Clinic
- Joseph D. Yao, MD of the Division of Clinical Microbiology at Mayo Clinic
Forward to a Colleague
If you have questions, e-mail